Expertise in Small to Medium Scale Chemical Manufacturing
Product SearchHelp?
Customer Login

New Additions to Range Of Novel Intermediates Announced


Daventry, UK and CPhI Worldwide, Frankfurt, October 2011 - Endeavour Speciality Chemicals (Endeavour) today announced the launch of new additions to its range of reactive intermediates which includes a set of novel carboxylic acid anhydrides. Aimed at researchers working to synthesize new biologically active substances with specific pharmacological activity, the anhydrides are most commonly utilized in their reaction with nucleophiles to form the corresponding acylated compound, where the nucleophile could be an amine, thiol or any number of other groups. The introductions join a long established group of reactive intermediates that have been well reviewed in the past.

Recent literature has highlighted the role anhydrides can play in the synthesis of Melatonin agonists and antagonists (Melatonin is a hormone which plays an important role in aging, reproduction and sleep) and also their crucial role in the preparation of L-1,3-dioxolane-cytidine prodrugs, which are used in the treatment of various cancers, including those of the lung and pancreas. Numerous examples of the central role anhydrides play in the synthesis of β-amino acids, which are used in the preparation of a wide range of biologically active substances, have also been reported in recent years.   Historically β-amino acids have been used as an intermediate in the synthesis of β-lactams – an important class of antibiotic - but they are now finding use in a diverse range of therapeutic areas, such as in the manufacture of (2R, 3R)-2-Amino-3-hydroxy-3-cyclohexylpropanoic acid, a key component of the HIV antagonist drug, ONO-4128.

“We are constantly designing and developing innovative products to meet the demands of research and discovery scientists as well as looking at new applications for our existing technologies” commented Endeavour Sales Manager, Jordi Robinson. “The new range of anhydrides illustrates the diversity of our capabilities across a wide range of market segments and we are currently working on a strategy to potentially add significant numbers of new items to our range in 2012.”

With the introduction of the new products, Endeavour will have added over 100 original compounds to its catalogue of over 850 products since the CPhI Worldwide 2010 event in Paris.  Designed for the synthesis of complex molecules, the majority of Endeavours’ products are based on its core technologies of sulphur and heterocyclic chemistry and are often unavailable from other manufacturers.  The new, non-exclusive products will be available from stock in small packs (1g - 100g) for early stage R&D or larger quantities (100g - 100kg) for projects moving through the development stage.

 Endeavour’s products have applications across industry sectors, including pharmaceuticals, agrochemicals and materials sciences. Together with parent company, Robinson Brothers, Endeavour can support projects from initial development through to full-scale commercial production and both companies have extensive experience in both Sulphur and Heterocyclic chemistries. Endeavour is also recognised as a market leader in Hydrogenation technology.


© Endeavour Speciality Chemicals Ltd
Endeavour Speciality Chemicals Ltd
Unit 12, Low March Industrial Estate
Daventry, Northants NN11 4SD UK

P: +44 (0)1327 310 079
F: +44 (0)1327 310 701
Endeavour Speciality Chemicals Ltd is part of the Robinson Brothers Group

Robinson Brothers

Web Design by 1PCS
{**} {**}